Every country faces the same fundamental challenge in the face of the COVID-19 pandemic. Their economies and societies cannot fully return to “normal” until we have a safe and effective vaccine. And achieving that goal quickly is not easy. We see four big problems.
CGD Policy Blogs
With so much uncertainty around COVID-19, it helps to focus on decisions that no one will regret later on, that are right whether the crisis is short or long, the recession deep or shallow. These are “no-regret policies.”
Despite decades of investment, TB remains a global crisis. Each year, TB kills 1.6 million people—making it the world’s deadliest infectious diseases. We have set out to develop a solution: what we ultimately called the Market-Driven, Value-Based Advance Commitment (MVAC), a mechanism to create and guarantee a market for better TB treatment, if and when such a treatment becomes available.
Gavi, The Vaccine Alliance: Doubling Down on Coverage, Partnerships, and Transition Incentives for the Next Phase
With the Global Fund and Global Polio Eradication Initiative replenishments successfully concluded, donors are turning their attention to the Gavi Alliance whose third replenishment process is scheduled to culminate in summer 2020. As the final Gavi Board meeting of 2019 kicks off next week, it’s time to sharpen goals and double down on strategies to enhance the partnership’s public health impact.
Over the past two decades, several global health institutions have attempted to improve public health by influencing the characteristics of health product markets, including pricing, quality, overall production, and the supplier and product landscapes. We examine the role of Gavi, the Vaccine Alliance in market shaping.
Cribsheet author and economist Emily Oster on the data behind health recommendations for pregnant women, how to balance children's and parents' needs, and how policymakers can empower parents to make good decisions for their families.
On Wednesday, Gavi, the Vaccine Alliance, will kick off its biannual Board meeting. This meeting includes a particularly important milestone: members will approve the 2021-2025 strategy, the so-called “Gavi 5.0”, to motivate the organization’s replenishment and set out a five-year program of work.
In March, our team at the Center for Global Development and Office of Health Economics posted a consultation draft of a policy proposal for a Market-Driven, Value-Based Advanced Commitment (MVAC). The MVAC is a new mechanism that puts middle-income country governments in the driver’s seat to accelerate R&D for diseases that affect the world’s poor—specifically, the 10 million men, women, and children who develop tuberculosis (TB) disease each year and desperately need better therapies.
The Board of Gavi, The Vaccine Alliance, will retreat next week to discuss a new strategy and replenishment. My colleagues and I have put together a preliminary set of six short notes that examine different dimensions of Gavi’s work and make recommendations for ways to address identified issues.
In December 2018, the Gavi Alliance hosted a mid-term review to assess progress towards its core purpose: “reach every child everywhere with vaccines against preventable diseases.” The good news is that there’s been advances on new vaccine introductions, and an estimated 65 million children were immunized with Gavi-supported new and underutilized vaccines in 2017. The bad news? There is still huge variability on the measure that counts most for building herd immunity and reducing vaccine-preventable disease: full vaccination for age among children under 2 years old.